Oz scientists develop world first cure for dengue fever

For Immediate Release: September 25, 2013

Leading Australian scientists develop world first cure for dengue fever

A team of Queensland scientists led by renowned microbiologist Professor Max Reynolds have developed the world’s first cure for dengue fever by distilling Melaleuca alternifolia leaves from Australia’s native tea tree plant.

Now available worldwide, 98alive™ is a unique natural medicine containing Melaleuca alternifolia leaf concentrate that’s antiviral, antibacterial and immune boosting properties have been scientifically proven to cure all four strains of dengue fever.

Professor Reynolds states the product is a significant breakthrough in treating dengue fever, a disease transferred to humans through A.aegypti mosquitoes which is estimated to effect 390 million people every year and is particularly prevalent throughout Asia.

“Prior to 98alive™ there was no cure or vaccine against dengue fever which we felt needed to be addressed given that 40 per cent of the world’s population live in the dengue danger zone around the equator,” Professor Reynolds said. “Adding to this, many of these at risk countries such as India and Indonesia also suffer high fatality rates due to current treatments not being affordable, effective or easily accessible.

“98alive™ is taken in capsule form, so it is easy to administer,” Professor Reynolds continued. “It has been proven to commence elimination of the virus within ten minutes of being taken, which not only reduces the chance of the disease becoming life threatening but also prevents it from spreading.”

Presenting the research behind 98alive™ at Airlangga University’s Centre of Excellence Conference in Indonesia on November 2 and 3, Professor Reynolds states the medicine’s immune boosting properties means it is also highly effective in preventing dengue fever.

“98alive™ primarily strengthens the immune system and therefore the recipient’s ability to fight the viral infection,” Professor Reynolds said. “This means that travellers or people living in at risk areas can take 98alive™ as a means of preventing dengue fever and to build up a resistance to the disease.”

This benefit of 98alive™ is particularly compelling given that the infection rate of dengue fever increased 30 fold from 1960 to 2010 and has been projected to increase even further as global warming causes the habitat for mosquitoes to expand. Professor Reynolds states that 98alive™’s unique make up of 98 active compounds is what makes it such an effective and fast acting treatment against the symptoms of dengue fever which include fever, headaches, muscle pain and rashes.

“Our unique process of distilling the Melaleuca alternifolia leaves ensures that the end result retains the plant’s highly beneficial antiviral, antibacterial, anti-inflammatory and antioxidant properties whilst removing the bulk of the potentially toxic monoterpene components that have, until now, prevented it from being consumed,” Professor Reynolds said.

98alive™ is the only Melaleuca alternifolia based medicine that is listed on the Australian Register of Therapeutic Goods (Australian Licence 202131) and that is recognised by the United States’ Food and Drug Administration as safe for human consumption.

Developed in Australia, which is known for its strict medical and product regulations, 98alive™ has undergone rigorous testing at world leading research facilities in Australia, the United States and in Asia.

98alive™ is available globally on both an individual and commercial scale. For more information on 98alive™, please visit www.98alive.com.

ENDS

© Scoop Media